Why Pharma Sales Must Evolve
For decades, the traditional directive for pharmaceutical and medical device sales reps has been straightforward: prioritize the Decile 10 prescribers. The logic seems sound on the surface, as high historical prescription volume equates to high priority. However, in today’s complex healthcare landscape, this relentless pursuit of top-tier volume is often holding our most talented sales teams back.
We need to rethink how we utilize our field representatives and inspire them to be strategic thinkers, rather than just executors of outdated call plans.
The “Fool’s Gold” of Pure Volume
The traditional concept of deciling is based almost entirely on historical script data volume. While a Decile 10 physician might write a massive number of prescriptions, they are often entrenched with competitors or simply impossible to reach. A Decile 10 HCP has made their decisions.
When sales management mandates high call frequencies on these specific doctors, reps end up chasing “fool’s gold”. This creates a massive point of friction between field reps who know firsthand that a certain Decile 10 is a “no-access doctor” and management, who continues to mandate weekly call frequency metrics.
The result?
Reps are forced into a “check-the-box” mentality, logging superficial touchpoints just to satisfy CRM quotas rather than doing the deep, consultative work they were hired to do.
The Hidden Upside of Lower Decile HCPs
What happens when we empower reps to look beyond pure volume? During a recent discussion with sales leadership, a powerful anecdote emerged regarding territory strategy. A sales manager heavily questioned a rep’s decision to allocate entertainment budget and significant time toward a newly practicing, low-volume physician instead of focusing exclusively on the established Decile 10s.
However, the rep had uncovered a crucial strategic insight: this lower-decile doctor was highly accessible, progressive, and open to adopting new clinical pathways.
Over time, that low-volume physician became one of the top prescribers in the territory.
When we equip reps with contextual and pertinent strategies that incorporate factors like accessibility, brand agnosticism, and growth potential alongside raw script volume, they can optimize and justify focus on lower-decile, high-potential targets.
A “Decile 5” doctor who actually has the time to sit down and discuss patient outcomes is potentially more valuable than a Decile 10 doctor who takes a bite of the sandwich, forces the rep to leave a brochure with the receptionist, and asks for samples.
The Birth of Sales Reps as Clinical Consultants
The industry relies too heavily on reps delivering “samples, slogans, and sandwiches” during 20-second hallway interactions. If we want to inspire our sales teams, we need to treat them like the clinical consultants they are capable of being.
To do this, leadership must shift the focus from rudimentary activity metrics to actionable intelligence. When reps are given compiled data insights that provide a well-rounded picture of a physician’s practice, it fundamentally changes how they operate. They are no longer blindly following a call list; they are analyzing the market, strategizing their outreach, and engaging in meaningful peer-to-peer dialogues that actually move the needle for patient care.
It is time to evolve beyond the rigid Decile 10 playbook. By redefining how we measure a physician’s potential and trusting our reps to strategize with better data, we can eliminate the friction between management and the field. Let’s give our sales teams the tools to stop chasing fool’s gold and start building the high-value partnerships that modern healthcare demands.